AVROBIO, Inc.

Novartis was a pioneer in gene therapy with the successful development of Zolgensma (onasemnogene abeparvovec-xioi) for spinal muscular atrophy. And while some big pharmas have backed away from the sp

Alumis, Inc. planned to raise between $282.4m and $317.7m in the last biopharmaceutical initial public offering in the US during the first half of 2024, but instead grossed $250m on 27 June from the

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bristol, VantAI Pair Technologies In Pr

The number of biopharma initial public offerings in the US in 2024 grew to four with IPOs by Alto Neuroscience Inc. and Fractyl Health , showing that investors continue to be supportive of certain